Stock 460 SIHUAN PHARMACEUTICAL HOLDINGS GROUP LTD.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Sihuan Pharmaceutical Holdings Group Ltd. Shanghai - Hong Kong Stock Connect

Equities

460

BMG8162K1137

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Chinese Regulator Approves Drug Registration for Sihuan Pharmaceutical's Subsidiary's Ticagrelor Orodispersible
MT
Sihuan Pharmaceutical Holdings Group Ltd.'s Honghe Pharmaceutical Co., Ltd. Obtains Drug Registration Approval from National Medical Products Administration
CI
Sihuan Pharmaceutical Holdings Group Ltd. commences an Equity Buyback Plan for 932,999,920 shares, representing 10% of its issued share capital, under the authorization approved on June 7, 2024.
CI
Sihuan Pharmaceutical Unit Gets Nod for Weight-Loss Drug Application in China
MT
Sihuan Pharma Subsidiary Licenses Fadanafil Drug to Livzon Pharmaceutical Unit
MT
Xuanzhu Biopharmaceutical Co., Ltd. and Livzon Group Livzon Pharmaceutical Factory Reaches an Exclusive Licensing Cooperation on Fadanafil
CI
Chinese Regulators Approve Sihuan Pharmaceutical’s Drug Registration Application
MT
Sihuan Pharmaceutical Holdings Group Ltd. Announces Rivaroxaban Tablets (Strength: 2.5Mg) Obtained Drug Registration Approval from NMPA
CI
Chinese drugmakers developing generic drugs of Novo Nordisk's Ozempic
RE
Novo Nordisk braces for generic challenge to Ozempic, Wegovy in China
RE
Sihuan Pharmaceutical, Unit Withdraw Latter's Stock Exchange Bid, Shares Down by Over 3%
MT
Sihuan Pharmaceutical Unit's Lung Cancer Drug NDA Accepted by NMPA, Stocks Shoot Over 10%
MT
Sihuan Pharma Unit Wins Bid to Supply Insulin Products to Chinese Government
MT
Sihuan Pharmaceutical Narrows 2023 Loss on Absence of Asset, Investment Impairments
MT
Sihuan Pharmaceutical Holdings Group Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Sihuan Pharmaceutical's RF Device Wins Registration Approval in China
MT
Sihuan Pharmaceutical Holdings Unit Forms Consortium for Ji Yao Restructuring
MT
China Approves Drug Registration for Sihuan Pharmaceutical Unit's Type 2 Diabetes Drug
MT
Sihuan Pharmaceutical Holdings Group Ltd. Receives Registration Approval from National Medical Products Administration for Proline Janagliflozin Tablets
CI
China Includes Four Injectables by Sihuan Pharma Associate in Drug Reimbursement List; Shares Rise 3%
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 460 Stock
  4. 460 Stock
  5. News Sihuan Pharmaceutical Holdings Group Ltd.